BioSpace News Archive

Nabriva Therapeutics plc announced its financial results for the three months ended March 31, 2022 and provided a corporate update.

CareDx, Inc reported financial results for the first quarter ended March 31, 2022.

Global Blood Therapeutics, Inc. announced that on May 1, 2022, the compensation committee of GBT’s board of directors granted 14 new employees restricted stock units for an aggregate of 46,400 shares of the company’s common stock.

Simulations Plus, Inc. (Nasdaq: SLP), today announced that the U.S. Food and Drug Administration (FDA) has renewed its licenses to the DILIsym® software platform, the DILIsym Services division’s flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI).

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18 F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer.

InterVenn Biosciences, the leader in glycoproteomics, today announced Aldo Carrascoso, Co-Founder and CEO, will present at the Bank of America 2022 Healthcare Conference on Tuesday, May 10, 2022 in Las Vegas, NV.

Enlivex Therapeutics Ltd. today announced the issuance of U.S. Patent Nos. 11,304,976 and 11,318,163.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its first quarter 2022.

NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX) will report its results for the first quarter ended March 31, 2022 before market on Thursday, May 19, 2022.

Coherus BioSciences, Inc., reported financial results for the quarter ended March 31, 2022 and recent business highlights.